KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Operating Income: 2009-2024

Historic Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 16 years, with Dec 2024 value amounting to $716.6 million.

  • Jazz Pharmaceuticals' Operating Income fell 77.90% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.6 million, marking a year-over-year decrease of 30.19%. This contributed to the annual value of $716.6 million for FY2024, which is 23.86% up from last year.
  • Per Jazz Pharmaceuticals' latest filing, its Operating Income stood at $716.6 million for FY2024, which was up 23.86% from $578.6 million recorded in FY2023.
  • Jazz Pharmaceuticals' 5-year Operating Income high stood at $716.6 million for FY2024, and its period low was -$65.5 million during FY2022.
  • For the 3-year period, Jazz Pharmaceuticals' Operating Income averaged around $409.9 million, with its median value being $578.6 million (2023).
  • Per our database at Business Quant, Jazz Pharmaceuticals' Operating Income slumped by 138.48% in 2022 and then skyrocketed by 982.95% in 2023.
  • Over the past 5 years, Jazz Pharmaceuticals' Operating Income (Yearly) stood at $378.1 million in 2020, then crashed by 54.96% to $170.3 million in 2021, then tumbled by 138.48% to -$65.5 million in 2022, then surged by 982.95% to $578.6 million in 2023, then rose by 23.86% to $716.6 million in 2024.